Market Research Report
Estrogen Receptor - Pipeline Review, H2 2019
|Estrogen Receptor - Pipeline Review, H2 2019|
Published: December 27, 2019
Global Markets Direct
Content info: 91 Pages
Delivery time: 1-2 business days
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter. It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP.
Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 27 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5, 6, 7 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Women's Health and Male Health which include indications Breast Cancer, Metastatic Breast Cancer, Osteoporosis, Hormone Sensitive Breast Cancer, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Demyelinating Diseases, Ductal Carcinoma In Situ, Endometrial Cancer, Endometriosis, Fallopian Tube Cancer, Hepatocellular Carcinoma, Male Hypogonadism, Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neuromyelitis Optica (Devic's Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Uterine Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).
The latest report Estrogen Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.